Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 712 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
This article has been cited by
1Novel Exenatide Analogs with Peptidic Albumin Binding Domains: Potent Anti-Diabetic Agents with Extended Duration of Action
Odile E. Levy,Carolyn M. Jodka,Shijun Steven Ren,Lala Mamedova,Abhinandini Sharma,Manoj Samant,Lawrence J. D’Souza,Christopher J. Soares,Diane R. Yuskin,Li Jenny Jin,David G. Parkes,Krystyna Tatarkiewicz,Soumitra S. Ghosh,Nigel Irwin
PLoS ONE.2014;9(2)e87704
[DOI]
2Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
Seungah Lee,Dong Yun Lee
Annals of Pediatric Endocrinology & Metabolism.2017;22(1)15
[DOI]
3Liraglutide treatment and acylcarnitine profiles in Egyptian obese insulin-resistant females
Neveen A. Hussein,Samia A. Ebied,Hoda A. Nour,Usama K. Zaki,Sahar M. EL-Kotishy,Tarek M. Salem
European Journal of Pharmacology.2021;891(1)173668
[DOI]
4Laminarin counteracts diet-induced obesity associated with glucagon-like peptide-1 secretion
Liusong Yang,Lina Wang,Canjun Zhu,Junguo Wu,Yexian Yuan,Lulu Yu,Yaqiong Xu,Jingren Xu,Tao Wang,Zhengrui Liao,Songbo Wang,Xiaotong Zhu,Ping Gao,Yongliang Zhang,Xiuqi Wang,Qingyan Jiang,Gang Shu
Oncotarget.2017;8(59)99470
[DOI]
5Polymeric microparticle systems for modified release of glucagon-like-peptide-1 receptor agonists
Luis Peña Icart,Fernando Gomes Souza,Luís Maurício T. R. Lima
Journal of Microencapsulation.2021;8(59)1
[DOI]
6Mechanistic insights into the pH-dependent membrane peptide ATRAM
Vanessa P. Nguyen,Loganathan Palanikumar,Stephen J. Kennel,Daiane S. Alves,Yujie Ye,Jonathan S. Wall,Mazin Magzoub,Francisco N. Barrera
Journal of Controlled Release.2019;298(59)142
[DOI]
7Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes
Chris de Graaf,Dan Donnelly,Denise Wootten,Jesper Lau,Patrick M. Sexton,Laurence J. Miller,Jung-Mo Ahn,Jiayu Liao,Madeleine M. Fletcher,Dehua Yang,Alastair J. H. Brown,Caihong Zhou,Jiejie Deng,Ming-Wei Wang,RICHARD DEQUAN YE
Pharmacological Reviews.2016;68(4)954
[DOI]
8Pre-Clinical Evaluation of a Modified Cyclodextrin-Based Nanoparticle for Intestinal Delivery of Liraglutide
Elena Presas,Sulay Tovar,Juan Cuñarro,Joseph P. O'Shea,Caitriona M. O'Driscoll
Journal of Pharmaceutical Sciences.2021;110(1)292
[DOI]
9Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis
Carrie McAdam-Marx,Hiep Nguyen,Marisa B. Schauerhamer,Mukul Singhal,Sudhir Unni,Xiangyang Ye,David Cobden
Clinical Therapeutics.2016;38(12)2642
[DOI]
10Glucagon-like peptide-1 mimetics, optimal for Asian type 2 diabetes patients with and without overweight/obesity: meta-analysis of randomized controlled trials
Fang Zhang,Lizhi Tang,Yuwei Zhang,Qingguo Lü,Nanwei Tong
Scientific Reports.2017;7(1)2642
[DOI]
  Feedback 
  Subscribe 

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal